Evidence map›Paper›PMID 31199346›Full record

ArticleJMIR research protocols2019

Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial.

Andrew Farmer, Kirsty Bobrow, Natalie Leon, Nicola Williams, Enita Phiri, Hazel Namadingo, Sara Cooper, John Prince, Amelia Crampin, Donela Besada and 9 more

Abstract read
In one paragraph

Article in JMIR research protocols, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Andrew Farmer *Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.ORCID http://orcid.org/0000-0002-6170-4402
Kirsty Bobrow *Chronic Disease Initiative for Africa, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0002-2452-2482
Natalie LeonSouth African Medical Research Council, Cape Town, South Africa.ORCID http://orcid.org/0000-0001-9392-3426
Nicola WilliamsNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.ORCID http://orcid.org/0000-0002-7476-9715
Enita PhiriMalawi Epidemiology and Intervention Research Unit, Lilongwe, Malawi.ORCID http://orcid.org/0000-0002-1970-146X
Hazel NamadingoMalawi Epidemiology and Intervention Research Unit, Lilongwe, Malawi.ORCID http://orcid.org/0000-0002-1799-8458
Sara CooperSouth African Medical Research Council, Cape Town, South Africa.ORCID http://orcid.org/0000-0001-9894-236X
John PrinceInstitute of Biomedical Engineering, Oxford, United Kingdom.ORCID http://orcid.org/0000-0002-3203-8754
Amelia CrampinMalawi Epidemiology and Intervention Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID http://orcid.org/0000-0002-1513-4330
Donela BesadaSouth African Medical Research Council, Cape Town, South Africa.ORCID http://orcid.org/0000-0002-2020-5244
Emmanuelle DaviaudSouth African Medical Research Council, Cape Town, South Africa.ORCID http://orcid.org/0000-0002-6335-4581
Ly-Mee YuNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.ORCID http://orcid.org/0000-0003-0331-7364
Jonathan NgomaKamuzu Central Hospital, Lilongwe, Malawi.ORCID http://orcid.org/0000-0002-3469-4384
David SpringerThe Boston Consulting Group, London, United Kingdom.ORCID http://orcid.org/0000-0002-7448-7398
Bruno PaulyDepartment of Diabetes and Endocrinology, Chris Hani Baragwanath Academic Hospital, Johanesburg, South Africa.ORCID http://orcid.org/0000-0002-3282-9863
Shane NorrisSouth African Medical Research Council, Developmental Pathways for Health Research Unit, University of Witwatersrand, Johannesburg, South Africa.ORCID http://orcid.org/0000-0001-7124-3788
Lionel TarassenkoInstitute of Biomedical Engineering, Oxford, United Kingdom.ORCID http://orcid.org/0000-0002-0118-1646
Moffat NyirendaMalawi Epidemiology and Intervention Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID http://orcid.org/0000-0003-2120-4806
Naomi LevittChronic Disease Initiative for Africa, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0001-6480-8066

Funding

Medical Research Council MR/M016498/1
6 · The paper itself

Abstract

backgroundHealth outcomes for people treated for type 2 diabetes could be substantially improved in sub-Saharan Africa. Failure to take medicine regularly to treat diabetes has been identified as a major problem. Resources to identify and support patients who are not making the best use of medicine in low- and middle-income settings are scarce. Mobile phones are widely available in these settings, including among people with diabetes; linked technologies, such as short message service (SMS) text messaging, have shown promise in delivering low-cost interventions efficiently. However, evidence showing that these interventions will work when carried out at a larger scale and measuring the extent to which they will improve health outcomes when added to usual care is limited.

objectiveThe objective of this trial is to test the effectiveness of sending brief, automated SMS text messages for improving health outcomes and medication adherence in patients with type 2 diabetes compared to an active control.

methodsWe will carry out a randomized trial recruiting from clinics in two contrasting settings in sub-Saharan Africa: Cape Town, South Africa, and Lilongwe, Malawi. Intervention messages will advise people about the benefits of their diabetes treatment and offer motivation and encouragement around lifestyle and use of medication. We allocated patients, using randomization with a minimization algorithm, to receive either three to four intervention messages per week or non-health-related messages every 6 weeks. We will follow up with participants for 12 months, measuring important risk factors for poor health outcomes and complications in diabetes. This will enable us to estimate potential health benefits, including the primary outcome of hemoglobin A

resultsRecruitment to the trial began in September 2016 and follow-up of participants was completed in October 2018. Data collection from electronic health records and other routinely collected sources is continuing. The database lock is anticipated in June 2019, followed by analysis and disclosing of group allocation.

conclusionsThe knowledge gained from this study will have wide applications and advance the evidence base for effectiveness of mobile phone-based, brief text messaging on clinical outcomes and in large-scale, operational settings. It will provide evidence for cost-effectiveness and acceptability that will further inform policy development and decision making. We will work with a wide network that includes patients, clinicians, academics, industry, and policy makers to help us identify opportunities for informing people about the work and raise awareness of what is being developed and studied.

trial registrationISRCTN Registry ISRCTN70768808; http://www.isrctn.com/ISRCTN70768808 (Archived by WebCite at http://www.webcitation.org/786316Zqk). INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/12377.

Indexed as

diabetes mellitusmobile healthrandomized controlled trialtreatment adherencetype 2 diabetes

Identifiers

PMID31199346
PMCPMC6592392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.